STELLA PHARMA CORPORATION Logo

STELLA PHARMA CORPORATION

Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.

4888 | T

Overview

Corporate Details

ISIN(s):
JP3399680002
LEI:
Country:
Japan
Address:
大阪市中央区高麗橋三丁目2番7号 ORIX高麗橋ビル
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stella Pharma Corporation is a pharmaceutical company engaged in the research, development, manufacturing, and sales of innovative drugs. The company specializes in Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment for cancer. Its primary focus is on the development of boron compounds, including its approved drug Steboronine®, which is administered to patients prior to neutron irradiation. This therapy is primarily used for treating unresectable, locally advanced, or recurrent head and neck cancer. Stella Pharma aims to contribute to global healthcare by advancing BNCT as a new standard of care for various types of cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 05:26
Registration Form
確認書
Japanese 8.2 KB
2025-11-14 05:25
Interim Report
半期報告書-第19期(2025/04/01-2026/03/31)
Japanese 202.7 KB
2025-06-26 07:06
Registration Form
確認書
Japanese 8.1 KB
2025-06-26 07:05
Annual Report
有価証券報告書-第18期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-06-26 07:05
Governance Information
内部統制報告書-第18期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-25 06:52
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2024-11-12 05:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-12 05:06
Interim Report
半期報告書-第18期(2024/04/01-2025/03/31)
Japanese 192.3 KB
2024-07-01 02:34
Post-Annual General Meeting Information
臨時報告書
Japanese 28.0 KB
2024-06-28 07:05
Governance Information
内部統制報告書-第17期(2023/04/01-2024/03/31)
Japanese 21.3 KB
2024-06-28 07:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 07:04
Annual Report
有価証券報告書-第17期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-02-14 05:13
Quarterly Report
四半期報告書-第17期第3四半期(2023/10/01-2023/12/31)
Japanese 145.0 KB
2024-02-14 05:13
Report Publication Announcement
確認書
Japanese 8.1 KB
2023-11-14 06:08
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all STELLA PHARMA CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for STELLA PHARMA CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for STELLA PHARMA CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.